about
Anatomy and Physiology of the Urinary Tract: Relation to Host Defense and Microbial InfectionSNX31: a novel sorting nexin associated with the uroplakin-degrading multivesicular bodies in terminally differentiated urothelial cellsLoss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation.Loss of p27 upregulates MnSOD in a STAT3-dependent manner, disrupts intracellular redox activity and enhances cell migration.Acrolein- and 4-Aminobiphenyl-DNA adducts in human bladder mucosa and tumor tissue and their mutagenicity in human urothelial cells.Temporally and spatially controllable gene expression and knockout in mouse urothelium.E3 ligase activity of XIAP RING domain is required for XIAP-mediated cancer cell migration, but not for its RhoGDI binding activityThe Chinese herb isolate isorhapontigenin induces apoptosis in human cancer cells by down-regulating overexpression of antiapoptotic protein XIAP.Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo.A new tumour suppression mechanism by p27Kip1: EGFR down-regulation mediated by JNK/c-Jun pathway inhibition.β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation.Interstitial calcinosis in renal papillae of genetically engineered mouse models: relation to Randall's plaquesRas mutation cooperates with β-catenin activation to drive bladder tumourigenesisChemoprevention of urothelial cell carcinoma growth and invasion by the dual COX-LOX inhibitor licofelone in UPII-SV40T transgenic miceTamm-Horsfall Protein Regulates Granulopoiesis and Systemic Neutrophil Homeostasis.Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer.Inhibition and Reversal of Microbial Attachment by an Antibody with Parasteric Activity against the FimH Adhesin of Uropathogenic E. coliOncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype CarcinomasUromodulin in kidney injury: an instigator, bystander, or protector?RhoGDI SUMOylation at Lys-138 increases its binding activity to Rho GTPase and its inhibiting cancer cell motility.Dual ligand/receptor interactions activate urothelial defenses against uropathogenic E. coliTP53 modulating agent, CP-31398 enhances antitumor effects of ODC inhibitor in mouse model of urinary bladder transitional cell carcinoma.Effect of CpG methylation at different sequence context on acrolein- and BPDE-DNA binding and mutagenesisCigarette side-stream smoke lung and bladder carcinogenesis: inducing mutagenic acrolein-DNA adducts, inhibiting DNA repair and enhancing anchorage-independent-growth cell transformation.High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum.Tamm-Horsfall protein translocates to the basolateral domain of thick ascending limbs, interstitium, and circulation during recovery from acute kidney injuryDecreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor.Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo.FGFR3b Extracellular Loop Mutation Lacks Tumorigenicity In Vivo but Collaborates with p53/pRB Deficiency to Induce High-grade Papillary Urothelial Carcinoma.Sequential and compartmentalized action of Rabs, SNAREs, and MAL in the apical delivery of fusiform vesicles in urothelial umbrella cellsCyclin d1 downregulation contributes to anticancer effect of isorhapontigenin on human bladder cancer cells.The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesisConformational inactivation induces immunogenicity of the receptor-binding pocket of a bacterial adhesin.Inhibition of PHLPP2/cyclin D1 protein translation contributes to the tumor suppressive effect of NFκB2 (p100).Kava chalcone, flavokawain A, inhibits urothelial tumorigenesis in the UPII-SV40T transgenic mouse model.Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis.Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin.Progress made in the use of animal models for the study of high-risk, nonmuscle invasive bladder cancer.On a FOX hunt: functions of FOX transcriptional regulators in bladder cancer.Neuropilin-VEGF signaling pathway acts as a key modulator of vascular, lymphatic, and inflammatory cell responses of the bladder to intravesical BCG treatment.
P50
Q26782602-BCA74AB3-A5BC-4DAA-8202-01D6319A0D28Q28589878-209259C4-CD8C-4773-BAED-F92A10D0C37BQ28730032-183BF965-D4BF-4B2C-808D-881153E6D49BQ33822389-23FB3FF3-034D-4EA2-B902-3565A9F7C9A6Q33976931-F9828DEF-92A6-40C8-80DB-60332B651240Q34085227-14B5B0DF-24F1-40A5-9A3B-A3B7670DAF81Q34245177-46BC9C84-9E32-452E-900F-88DCED5CAD9AQ34294301-A3F4A9D3-4EA9-432F-B51D-222439CFA7BDQ34365942-2E8E2C03-4043-48EE-82A2-03194C976511Q34406424-C2033A72-F154-4AEA-A2C3-A7034607E666Q34603174-B1C9BF07-70A7-48AE-A0D8-AB37BF68FB5CQ34857373-3326B8DE-1DB3-4CAA-A761-6A2544D73DA5Q35006427-08DF1349-5593-4058-B97E-4CD8AD3CBD01Q35027361-D0709311-3F26-499D-98A9-FC7D3F8952DAQ35537378-53D0F8AC-7B72-4102-BECE-0A5267425D94Q35568071-8C9E2A67-7DB2-4FEC-9646-3C53C0084CF8Q35606583-6ECAD9D3-D5AE-4DAF-ADA3-AA63D2DF5B25Q35612218-33159B16-7F3D-408C-ADDE-8FBF03ED4501Q35785284-331B5B5D-2230-4D28-884A-1A58E67640A2Q35922304-03BBDF41-02E1-4001-BBA6-7BCA77858B0DQ36262315-FC35EB88-0045-4DB5-BD1D-7541D3642A7AQ36309384-D348BE37-6690-467D-9B4D-71F800F65BBCQ36499798-3402D46A-2778-442A-9816-4409C13011E4Q36545118-5FF42972-16EA-4B78-A12A-2323973859D0Q36665063-586E3E0B-5BFB-4420-8410-AC22A71B5DE3Q36764208-333B00D5-32F2-468F-A1FF-504B67C28EF1Q36817627-1407814E-8794-4611-A843-E601B12BA377Q36820882-FCA2558A-1528-4E57-A68F-5DFC66FFB22CQ36882005-B72422D4-D6BC-4CE1-924B-719AA4453B8BQ36896310-0B9E43CD-088F-4B60-889C-0412B3A7AD46Q37096690-4BD47F32-7C50-49C1-8A66-93B6780A1766Q37220014-94D2FFD2-E399-48F8-BCF0-E757B282C70CQ37340809-F955237E-630D-4A5F-8BE7-B4B853E6F592Q37376213-A9FC49D0-FE4D-4834-AEE7-6F358BE878A7Q37416331-D1E52BD8-DD3D-4EF4-A364-8EBBAF2CB6A9Q37480033-4E3227DD-B909-4B60-B3AF-11A67BFFF8D6Q37737877-48425496-2B9D-461D-8655-136BD1BA590BQ38219686-3A98CF1D-7945-499D-B3AD-E43122624D86Q38789453-A5D7C89A-7EE7-457B-85B2-DCAAE7B16E7EQ39652806-B19CCB7D-5568-4FC3-A44D-674A61139B8B
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Xue-Ru Wu
@en
Xue-Ru Wu
@nl
type
label
Xue-Ru Wu
@en
Xue-Ru Wu
@nl
prefLabel
Xue-Ru Wu
@en
Xue-Ru Wu
@nl
P31
P496
0000-0001-6058-6291